Recruitment status changed
Before: Active not recruiting. After: Terminated.
Among the trials TrialRedline tracks, 71 changed their ClinicalTrials.gov record in August 2026: 5 status changes to terminated, withdrawn or suspended, 10 primary outcome text edits, 16 completion dates moved later, 3 completion dates moved earlier, 20 enrollment changes, 35 other status changes. Each entry shows the previous and updated value and links to the registry's own version comparison.
5 in August 2026. Recruitment status changed to Terminated, Withdrawn or Suspended. Terminated first, then newest.
Before: Active not recruiting. After: Terminated.
Before: Enrolling by invitation. After: Terminated.
Before: Recruiting. After: Terminated.
Before: Recruiting. After: Terminated.
Before: Active not recruiting. After: Terminated.
10 in August 2026. The text of the main study measures changed. Edits to capitalization, punctuation or spacing alone are left out. Newest first.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Progression-free survival (PFS) as assessed by Independent Review Committee (IRC). After: Measure: Progression-free survival (PFS) as assessed by Independent Review Committee (IRC) Measure: Objective response rate (ORR) without partial response with lymphocytosis (PR-L) as assessed by IRC.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from Baseline in performance on the Cogstate Cognition battery*. After: Measure: Change from Baseline in performance on the Cogstate Cognition battery* Measure: Change from Baseline in PROMIS Cognitive Function Short Form 8a (SF-8a) Measure: Change from Baseline in PROMIS Fatigue Short Form 13a (SF-13a) Measure: Change from Baseline in PROMIS Sleep Disturbance Short Form 8a (SF-8a) Measure: Change from Baseline in SF-12 Health Survey (Physical Component Scores) Measure: Change from Baseline in SF-12 Health Survey (Mental Component Scores) Measure: Change from Baseline in DePaul Symptom Questionnaire (DSQ) Post-Exertional Malaise Measure: Composite Benefit Score.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change in Montgomery-Åsberg Depression Rating Scale (MADRS) score. Measure: Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuations.. After: Measure: Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Score..
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Part A: Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) Measure: Part B: Area under the concentration-time curve (AUC) of C-peptide after a 2 hour mixed meal tolerance test (MMTT). After: Measure: Part A: Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) Measure: Part B: Area under the concentration-time curve (AUC) of C-peptide after a 2 hour mixed meal tolerance test (MMTT) Measure: Part C: Area under the concentration-time curve (AUC) of C-peptide after a 2-hour mixed meal tolerance test (MMTT)..
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To evaluate incidence of adverse events. After: Measure: Phase 1/2: To evaluate incidence of adverse events Measure: Phase 2b Sub-study: To evaluate the efficacy of CABA-201 on % predicted forced vital capacity (FVC) in SSc-ILD subjects.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Relative (%) change in liver stiffness by VCTE compared to baseline at Week 24. After: Measure: Relative (%) reduction in liver stiffness by VCTE compared to baseline.
NCT06757010 · BioVie Inc. (BIVI)
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from baseline in the MDS-UPDRS Part III. After: Measure: Monocyte Lymphocyte Ratio (MLR).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Occurrence of treatment emergent AEs (TEAEs). After: Measure: Percentage of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs) Measure: Percentage of Participants With ≥1 Serious Adverse Events (SAEs).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Long-term Safety. After: Measure: Time from randomization to relapse of binge eating in the RW segment.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change in AHI, Combined AD109 Dose Arms vs. Combined Placebo Arms. After: Measure: Change in Apnea-Hypopnea Index (AHI4) From Baseline: Combined AD109 Arms vs. Placebo.
16 in August 2026. Primary completion date moved later while its type (estimated or actual) stayed the same. Largest move first.
Before: 30 Dec 2025. After: 30 Dec 2026.
Before: 31 Mar 2027. After: 30 Sep 2027.
Before: 30 Jul 2026. After: 30 Dec 2026.
Before: 30 Jun 2026. After: 31 Oct 2026.
Before: 30 May 2027. After: 31 Jul 2027.
Before: Jul 2026. After: Jan 2027.
Before: Jun 2027. After: Mar 2028.
Before: Jun 2026. After: Jun 2027.
Before: Dec 2029. After: Feb 2031.
Before: Jun 2026. After: Sep 2026.
Before: Aug 2026. After: Oct 2026.
Before: Dec 2026. After: Dec 2027.
Before: Apr 2027. After: 31 May 2027.
Before: Dec 2026. After: Dec 2031.
Before: Jun 2026. After: Aug 2026.
Before: Jun 2026. After: Dec 2026.
3 in August 2026. Primary completion date moved earlier while its type stayed the same. Largest move first.
Before: 1 Dec 2027. After: 21 Jan 2027.
Before: Apr 2027. After: Jan 2027.
Before: Jun 2027. After: Mar 2027.
20 in August 2026. The participant count changed. Planned and actual counts are shown as recorded. Newest first.
Before: 150 participants (planned). After: 122 participants (actual).
Before: 60 participants (planned). After: 64 participants (actual).
Before: 260 participants (planned). After: 333 participants (actual).
Before: 108 participants (planned). After: 120 participants (planned).
Before: 3 participants (planned). After: 4 participants (actual).
Before: 55 participants (planned). After: 65 participants (planned).
Before: 160 participants (planned). After: 168 participants (actual).
Before: 12 participants (planned). After: 37 participants (planned).
Before: 100 participants (planned). After: 121 participants (actual).
Before: 60 participants (planned). After: 70 participants (actual).
Before: 220 participants (planned). After: 98 participants (actual).
Before: 165 participants (planned). After: 325 participants (planned).
NCT06757010 · BioVie Inc. (BIVI)
Before: 60 participants (planned). After: 57 participants (actual).
Before: 333 participants (actual). After: 337 participants (actual).
Before: 300 participants (planned). After: 236 participants (planned).
Before: 230 participants (planned). After: 255 participants (actual).
Before: 255 participants (planned). After: 258 participants (actual).
Before: 250 participants (planned). After: 65 participants (actual).
Before: 250 participants (planned). After: 253 participants (actual).
Before: 750 participants (planned). After: 2250 participants (planned).
35 in August 2026. Any other change of recruitment status, such as recruiting to completed. Newest first.
Before: Not yet recruiting. After: Recruiting.
Before: Terminated. After: Completed.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Active not recruiting. After: Completed.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Active not recruiting. After: Completed.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Enrolling by invitation.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Active not recruiting. After: Recruiting.
Before: Recruiting. After: Active not recruiting.
NCT06757010 · BioVie Inc. (BIVI)
Before: Active not recruiting. After: Completed.
Before: Not yet recruiting. After: Recruiting.
Before: Recruiting. After: Completed.
Showing 25 of 35. Browse all tracked trials to open the rest.
TrialRedline, “Clinical trial registry changes: August 2026”. https://trialredline.com/reports/2026-08
Based on public ClinicalTrials.gov record history. How we collect and check the data